A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

Aptevo Therapeutics (APVO) announced 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid ...

Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing ...